Novartis slips after pelacarsen Phase 3 setback
Novartis traded at $159.99 after pelacarsen flopped in a pivotal Phase 3 cardiovascular trial. Reuters estimated about CHF4.9 billion evaporated from market value as Zurich-listed shares fell 1.9%.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.